Table 1

Vaginal application of FSL-1 significantly delayed HSV-2 disease development and increased survival times.

FSL-1 and vehicle groupsa

Time to symptomsb

Survival timec

Survivald

(days)

(days)

(%)


FSL-1 2 μg 24 h prior

8.0 (6.4-9.7)e, f

9.4 (7.8-11.0)e, f

1/10 (10)

FSL-1 2 μg 6 h prior

9.0 (8.1-9.9)e, f

10.1 (8.9-11.3)e, f

0/10 (0)

FSL-1 2 μg 1 h prior, 1 h after

6.0 (5.5-6.4)

7.3 (6.8-7.7)

0/10 (0)

FSL-1 2 μg 6 h, 5 h, 4 h prior

6.4 (5.9-7.0)

9.1 (7.0-11.2)

1/9 (11)

FSL-1 6 μg 6 h prior

8.5 (6.7-9.9)e, f

10.0 (8.4-11.6)e, f

4/10 (40)

DPBS vehicle control

5.8 (5.0-6.4)

7.2 (6.9-7.6)

0/8 (0)


a Intravaginal application of FSL-1 or DPBS vehicle control at selected times prior to or after vaginal inoculation of HSV-2 (104pfu).

b Mean (95% confidence interval) for day that each mice first showed disease signs within 14d PI

c Mean (95% confidence interval) for day that each mice succumbed to disease within 14d PI.

d Number of mice that did not succumb to disease within 14d PI/total number of animals in the group (percent survival).

e p < 0.05 compared to DPBS vehicle control (ANOVA, Dunnett's Test).

f p < 0.05 compared to FSL-1 2 μg 1 h prior, 1 h after (ANOVA, Dunnett's Test).

Rose et al. Virology Journal 2009 6:195   doi:10.1186/1743-422X-6-195

Open Data